leisure time -WSS

leisure time

author：comprehensive 2025-10-01 04:13:10 - browse：94

When Prozac first entered the psychiatry scene in in the late ’80s, the profession was still Freud’s territory. Many considered taking medication to treat depression a failure. But that was all about to change, as early stewards like psychiatrist Peter Kramer refused to shy away from the new drug’s potential. These days, he says that people take for granted all of the progress that’s been made with antidepressant treatment in the past three decades.

“If you were going to be depressed any time in history and were interested in having an effective treatment, you would want to be alive now. But we’ve lost our wonderment about that,” said Kramer, the author of the groundbreaking 1993 book “Listening to Prozac.”

This week, Kramer joins me to discuss how the country’s relationship with antidepressants has changed since the publication of his book three decades ago. The conversation is based on his First Opinion, “What antidepressants are saying 30 years after the publication of ‘Listening to Prozac.’”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts. And don’t forget to sign up for the First Opinion newsletter to read each week’s best First Opinion essays.

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： STAT Summit: Biotech founders on deal

WSS

First Opinion Podcast: Long Covid needs a new approach

First Opinion Podcast: Long Covid needs a new approach

CEOs share strategies for surviving biotech slump

Hospital price transparency does save money, advocate argues

Senate committee scrutinizes Medicare Advantage brokers

Eli Lilly expects to double planned employment in Boston center

knowledge

leisure time

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pharmacists can make shortage drugs, but at what cost?

Anesthesiologist group: stop taking Ozempic before surgery

The EU Joint Clinical Assessment needs to live up to its promise

Cancer drug shortages should be causing more outrage

NIH confirmation hearing shows politicization of research

United colonoscopy coverage change 'may cost lives,' doctors say

Studies point to risks of excluding people with obesity from drug trials

Hepatitis C has a cure — but many Americans still lack access to it

HHS leader on health, climate change and biopharma emissions

entertainment

NIH confirmation hearing shows politicization of research

Hospital price transparency does save money, advocate argues

FDA struggles to regulate food additives, sometimes for decades

Hospital price transparency does save money, advocate argues

Why health workers in Gaza are injured or die at high rates

STAT Summit: Michael J. Fox on progress in Parkinson's research

focus

Wikipedia

explore

explore